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Cancer cells have higher reactive oxygen species (ROS) than normal
cells due to genetic and metabolic alterations. An emerging sce-
nario is that cancer cells increase ROS to activate pro-tumorigenic
signalingwhile activating antioxidant pathways tomaintain redox
homeostasis. Here we show that, in Basal-like and BRCA1-related
breast cancer (BC), ROS levels correlate with the expression and ac-
tivity of the transcription factor, Aryl hydrocarbon Receptor (AhR).
Mechanistically, ROS triggers AhR nuclear accumulation and acti-
vation to promote the transcription of both antioxidant enzymes
and the epidermal growth factor receptor (EGFR) ligand, am-
phiregulin (AREG). In a mouse model of BRCA1-related BC, cancer-
associated AhR and AREG control tumor growth and production
of chemokines to attract monocytes and activate pro-angiogenic
function of macrophages in the tumor microenvironment. Inter-
estingly, the expression of these chemokines as well as infiltration
of monocyte-lineage cells (monocyte and macrophages) positively
correlated with ROS levels in Basal-like BC. These data support
the existence of a coordinated link between cancer-intrinsic ROS
regulation and the features of tumor microenvironment. Thera-
peutically, chemical inhibition of AhR activity sensitizes human BC
models to Erlotinib, a selective EGFR tyrosine kinase inhibitor, sug-
gesting a promising combinatorial anti-cancer effect of AhR and
EGFR pathway inhibition. Thus, AhR represents an attractive target
to inhibit redox homeostasis and modulate the tumor promoting
microenvironment of Basal-like and BRCA1-associated BC.
triple negative breast cancer | aryl hydrocarbon receptor | reactive oxy-
gen species | tumor-associated macrophages | amphiregulin
INTRODUCTION
Cancer cells have a highly dynamic and heterogeneous
metabolism that enable them to generate energy, maintain
redox homeostasis and undertake biosynthesis (1, 2). In addition,
cancermetabolism has the ability to influence the communication
of the tumor cells with nearby immune cells by controlling the
nutrient status of the surrounding tumor microenvironment
(TME)(3-6). Hence, the study of cancer-associated metabolic
alterations has presented attractive therapeutic opportunities in
several pre-clinical models of cancers, including breast, colorectal
and lung cancer (7-9).
Among all forms of breast cancer (BC), the Basal-like (com-
monly being triple-negative based on defined markers; TNBC)
is generally more aggressive, of poor prognosis and frequenly
appears in women carriers of mutations in the tumor suppres-
sor BRCA1. More and more evidence supports the idea that
the study of TNBC dysregulated metabolism will lead to effica-
cious therapeutic approaches against this aggressive disease (10).
Compared to other BC subtypes, these cancers have increased
glutamine consumption and heightened sensitivity to glutamine
depletion(11). Moreover, in addition to BRCA1 mutations, this
subtype harbors loss-of-function mutations in Tp53 tumor sup-
pressor which together promote antioxidant responses(12, 13).
Therefore, Basal-like BC tends to accumulate higher levels of
reactive oxygen species because of its genetic and metabolic
alterations.
Here we found that human BC with low expression or inac-
tivation of BRCA1 specifically express aryl hydrocarbon receptor
(AhR), a ligand-activated transcription factor that regulates the
expression of a large superfamily of antioxidant molecules known
as cytochrome p450 proteins (CYP1A1, CYP1A2, and CYP1B1)
(14). In normal and malignant mammary cells, AhR activity is
triggered by ROS induced by glutathione deprivation or absence
of functional NRF2 antioxidant function. In the same conditions,
AhR directly promotes the expression of amphiregulin (AREG),
a ligand of the epidermal growth factor receptor (EGFR).
Using in vitro and in vivo models of basal-like/TNBC, we
demonstrate that AhR-AREG signaling pathway positively sup-
ports tumorigenesis by controlling ROS and shaping the pro-
tumorigenic functions of TME. Furthermore, chemical- and
genetically-induced AhR loss-of-function sensitizes tumor cells
Significance
Basal-like/BRCA1-associated breast cancer (BC) is a very ag-
gressive form of BC that frequently occurs in young women
with devastating effects. Since tailored therapies are lacking
for this type of tumor, scientists and clinicians are searching
for weaknesses that can be therapeutically exploited. Here we
describe the role of the transcription factor, Aryl hydrocarbon
Receptor (AhR), in supporting BC growth by controlling ROS
levels and the tumor-promoting features of the microenviron-
ment. In BC cells, AhR activation mediates the link between
intracellular ROS regulation and the pro-tumorigenic functions
of the surrounding immune system. We propose that tailored
inhibition of AhR-regulated pathways can lead to BC eradica-
tion by pushing it beyond its ROS tolerance limit and deprive
it of tumor-supporting immune cells.
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Fig. 1. AhR is activated by ROS in normal and malig-
nant mammary epithelial cells. (A) Cyp1a1mRNA lev-
els in mouse MEC left untreated (Ctr) or treated with
50μM and 200μM BSO for 24hr. (B) CYP1A1 mRNA
levels in human MCF10A cells treated left untreated
(Ctr) or treated 200μM BSO for 24h. (C) ChIP-qPCR
assay to detect AhR on Cyp1a1 promoter in COMMA-
1D cells treated with 200µM BSO for indicated time
points (n=3/group). ChIP with IgG antibody was used
as a negative control. (D) Representative images of im-
munocytochemistry analysis of AhR nuclear staining in
cells treatedwith BSO (200µMfor 2h) or left untreated
(Ctr). Bar graph shows the percentage of nuclear
AhR positive cells (n=100). Additional examples are
reported in SI Appendix, Figure S1 B. (E) Cyp1a1mRNA
levels in MEC that were isolated from Ahrf/fmice,
infected with Cre-expressing (+cre) or empty vector
control (-cre) adenoviruses, and then treated or not
with 50µM BSO for 24hr (n=3/group). (F) Immunoblot
showing AhR and CYP1A1 proteins in Nrf2+/+ or Nrf2-/-
MEC. Vinculin, loading control. (G) Cyp1a1 mRNA
levels in MEC isolated from Nrf2+/+or Nrf2-/- female
mice (n=5/genotype). (H) mRNA analysis of NRF2-
targets Gclm and Nqo1 in COMMA-1D cells that were
transfected with single guide RNA against mouse AhR
(sgAhR) and siRNA oligos specific for mouse Nrf2
(siNrf2) and then subjected to BSO (200µM) for 24h.
Cells manipulated with empty vector (EV) and non-
targeting (scramble, scr) siRNA were used as control.
n=3/group. (I) COMMA-1D cells were treated as in
(H), harvested 48h post-treatment and stained with
annexinV/7-AAD apoptosis detection kit. (J) Positive
association betweenAhR expression, AhR-curated tar-
gets, AhR-bound targets and the “ROS gene signature”
in basal-like and Homologous Recombination (HR)
Defective BC within the TCGA human BC dataset.
See Material and Methods for details. PCC=Pearson’s
Correlation Coefficient.
to erlotinib, an EGFR inhibitor, thus suggesting a promising
combinatorial anti-tumor strategy for the treatment of TNBC.
RESULTS
AhR is activated by ROS in normal and malignant mammary
cells
AhR redox activity has beenmainly associated with the detox-
ification of xenobiotics and pollutants (15), while NRF2 with
the regulation of glutathione metabolism (2). However, studies
of AhR or NRF2 knockout mice suggest a potential crosstalk
between these factors in the maintenance of redox homeostasis
(16). We found that long-term treatment of mouse and human
mammary epithelial cells (MEC) with buthionine sulfoximine
(BSO), a glutathione synthesis inhibitor (17) led to increased ex-
pression of AhR antioxidant target Cyp1a1 but did not affect Ahr
mRNA levels (Fig, 1A, B and SI Appendix, Fig. S1A). This was
due to the ability ofAhR to bind theCyp1a1 promoter as shown by
chromatin immunoprecipitation (ChIP) assay followed by qPCR
in cells treated with BSO at different time points (Fig. 1C). Com-
pared to IgG antibody control, AhR recruitment peaked at 1h
post-treatment, suggesting that BSO can trigger AhR transcrip-
tional activity as rapidly as the well-characterized AhR ligand,
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)(18, 19). Immuno-
cytochemistry assay showed a high frequency of cells positive
for nuclear AhR after 2h exposure to BSO when compared
to control conditions (Fig. 1D and SI Appendix, Fig. S1B). To
further test the specificity of AhR activation of Cyp1a1 by BSO,
we isolated primary MEC from the mammary glands of female
Ahr conditional knock-in mice (Ahrf/f) in which Cre recombinase
excises exon 2 encoding the basic domain responsible for DNA-
binding (20). As expected, Ahr exon 2 expression was found to be
relatively lower in Ahrf/f MEC infected with Cre-expressing ade-
novirus (SI Appendix Fig. S1C). In these settings, BSO-induced
upregulation of Cyp1a1 was significantly abrogated (Fig. 1D).
The evidence that AhR could respond to the intracellular
depletion of reduced glutathione prompted us to test the relation-
ship between AhR and NRF2 in the control of ROS levels in nor-
mal and malignant MEC. Compared to MEC isolated from Nrf2
wild-type (Nrf2+/+) female mice, MEC from Nrf2 null (Nrf2-/-)
mice did not express Nrf2 mRNA and accumulated both AhR
and Cyp1a1 proteins (Fig. 1E and SI appendix Fig. S1D). These
changes were associated with an increase in Cyp1a1mRNAwhile
AhR levels were not affected (Fig. 1F and SI Appendix Fig. S1E).
NRF2 bona fide target Hmox1 was downregulated while Nqo1
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Fig. 2. AREG expression is regulated by ROS-activated AhR and is elevated
in BRCA1-associated BC. (A) Areg mRNA levels in mouse MEC that were
left untreated (Ctr) or treated with the indicated doses of BSO for 24hr
(n=3/group). (B) Immunoblot showing AREG protein inmouseMEC that were
left untreated (Ctr) or treated with 200µM BSO for 24hr. Vinculin, loading
control. (C) Representative FACS profile of ROS levels in mouse cells treated
with 200µM BSO, with or without 250µM Trolox and stained with DCF-DA
after 24h. (D) Areg mRNA in mouse cells treated as in (C) (n= 3/group).
(E) ELISA measurement of secreted AREG protein in culture medium of
mouse cells treated as in (C) (n=5/group). (F) Areg mRNA levels in MEC that
were isolated from Ahrf/fmice, infected with Cre-expressing (+cre) or empty
vector control (-cre) adenoviruses, and treated or not with 50µM BSO for
24hr (n=3/group). (G) ChIP-qPCR assay to detect AhR on Areg promoter in
COMMA-1D cells treated with 200µM BSO and harvested at the indicated
time points (n=3/group). ChIP with IgG antibody was used as a negative
control. (H) Areg mRNA in MEC isolated from Nrf2+/+ or Nrf2-/- virgin female
mice (n=5/genotype). (I) AREG mRNA levels in TCGA BC grouped according
to low (bottom tertile) or high (top tertile) BRCA1 expression (n=1102).
(J) Representative images of IHC to detect AREG protein in samples from
a BRCA1 wild-type reduction mammoplasty from healthy women used as
controls, a prophylactic mastectomy in a woman heterozygous for a BRCA1
mutation (BRCA1 mutant), and a human BRCA1 mutant basal/TNBC breast
tumor. (K) Expression levels of AREG in Basal-like BC with “low ROS” or “high
ROS” based on the “ROS gene signature”.
mRNA was unaffected in Nrf2-/- as compared to Nrf2+/+ cells (SI
Appendix Fig. S1F,G). Then, the consequences of downregulated
Ahr and/or Nrf2, (separately or in combination) were assessed.
Fig. 3. AhR and AREG support tumorigenesis in a mouse model of BRCA1-
associated BC. (A) Levels of Areg and Cyp1a1 mRNAs in mouse MEC and
KBP cells (n=3/group). (B) Immunoblot showing AhR and AREG proteins
in lysates from KBP tumors transfected with empty vector (EV) and single
guide RNAs against mouse AhR (sgAhr) or Areg (sgAreg) and selected in
puromycin-containing media for three days. Vinculin, loading control. (C)
Representative plot of tumor volume increase over time in FVB female mice
transplanted with KBP cells expressing EV, sgAhr or sgAreg (n=4/group).
(D) Representative immunoflurorescence staining of nuclei (DAPI) and AREG
protein (red) in EV and sgAreg KBP tumors. (E) Immunoblot showing AhR
protein in lysates from EV and sgAhr KBP tumors. Vinculin, loading control.
(F) ELISA measurement of AREG protein in lysates from EV and sgAhr KBP
tumors.
Briefly, first we deleted Ahr by cell transfection with single guide
RNA (sgAhr) followed by puromycin selection, then we applied
Nrf2 siRNA (siNrf2) for one day prior BSO treatment. Control
cells (Ctr) were left untreated and additional controls were gen-
erated for Ahr and Nrf2 downregulation by applying an empty
sgRNA vector (EV) and a non-targeting (scramble, Scr) siRNA,
respectively. Cells were collected at 24h and 48h for RNA and
apoptosis analysis, respectively. Nrf2 mRNA levels were low in
siNrf2-transfected cells, as compared to Scr control (SI Appendix
Fig. S1H). Cyp1a1 expression was specifically affected by sgAhR
in both untreated (Ctr) and BSO-treated cells (SI Appendix Fig.
S1I). In EV+Scr cells, NRF2 targets Nqo1 and Gclm were prop-
erly upregulated by BSO treatment within 24h, while they were
not affected in sgAhr samples and marginally altered in siNrf2
cells. Low levels of both Ahr and Nrf2 dramatically decreased
BSO-induced Nqo1 and Gclm levels (Fig. 1G). This resulted in
a significant increase in apoptosis in Ahr/Nrf2-deleted cells as
measured by annexinV/7-AAD staining (Fig. 1H).
We next examined whether AhR activation could also be a
marker of oxidative stress in human basal-like/TNBC. The ex-
pression of AhR and its canonical targets, CYP1A1 and CYP1B1,
were found to be higher in BC with genetic mutations (Van’t Veer
dataset) or low expression (TCGA cohort) of BRCA1 gene (SI
Appendix Fig. S1J,K). Through bioinformatics analysis of TCGA
data of of basal-like BC and BC with homologous recombination
DNA repair defects (HR-defective BC, see Methods for addi-
tional details), we found that expression of AhR gene and two
AhR-regulated gene sets positively correlated with an oxidative
stress gene expression signature (Fig. 1I)(21). Together, these
data indicate that both NRF2 and AhR may act as sensors of
oxidative stress in normal and malignant MEC.­
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Fig. 4. AhR-AREG axis influences the number and function of tumor-
associated macrophages. (A) Absolute numbers of CD11b+ F4/80+ cells in
normal mammary fat pad from wild-type virgin and nulliparous mouse
females and KBP tumor-bearing female mice (n≥5/group). (B) Percentages
of CD11b+ F4/80+ cells in the mammary fat pad and EV, sgAhr or sgAreg
KBP tumor-bearing mice (n≥5/group). (C) Percentages of the indicated
subpopulations of CD11b+ F4/80+ macrophages in the mammary fat pad
and EV, sgAhr or sgAreg KBP tumor-bearing mice (n≥5/group). (D) Left,
representative immunohistochemistry staining of CD163 (surface marker
for human macrophages) and AREG staining in a human primary BRCA1-
mutated BC. Nuclei were stained with DAPI. Right, total count of CD163-
positive (CD163+) macrophages in AREG positive (AREG+) or negative (AREG-)
areas in reduction mammoplastic (pre) or tumor tissues from BRCA1 mutant
carriers. “pix” denotes the distance in pixels from the centre of an AREG-
positive or negative region. See Materials and Methods and SI appendix
Fig. 4D for additional details. (E) Vegfa mRNA levels in BMDM cultured
alone (-), or after co-culture with KBP cells (+) for 24hr (n=3/group). (F)
Vegfa mRNA levels in BMDM after co-culture with KBP cells expressing EV,
sgAhr or sgAreg for 24hr (n=3/group). (G) Vegfa mRNA levels in BMDM that
were left untreated (-), treated with rAREG (50ng/ml) or ITE (10μM) for 24hr
(n=3/group). (H) Quantification of CD31staining intensity as an indicator of
angiogenesis in EV, sgAhr or sgAreg tumors (n≥5/group).
ROS-regulated AhR controls expression of the epidermal
growth factor receptor ligand, amphiregulin
Cells use non-toxic levels of ROS to activate specific signaling
pathways that regulate proliferation and malignant transforma-
tion (22). Furthermore, some studies have reported a correlation
between xenobiotic-induced AhR activation and high levels of
the epidermal growth factor receptor (EGFR) ligand, amphireg-
ulin (AREG)(23, 24). Therefore, we tested the hypothesis that
AhR could modulate the EGFR pathway in conditions of ox-
idative stress in addition to an antioxidant response. In primary
mouseMECand in non-tumorigenic human breast epithelial cells
(MCF10A), BSO greatly inducedAREGprotein levels (Fig. 2A,B
and SI Appendix Fig. S2A).
EGFR is a member of a large family of receptor tyrosine
kinases that also includes HER2 (ERBB2/NEU), ERBB3, and
Fig. 5. AhR-AREG axis regulates peripheral monocyte count in mammary
tumor-bearing animals. (A) Absolute number of CD11b positive (CD11b+)
monocytes in the peripheral blood of wild-type (WT) and KBP tumor-bearing
mice (n=5/group). (B) Absolute number of CD11b+ monocytes inmice bearing
mammary tumors derived from EV-, sgAhr- or sgAreg-transfected KBP cells
(n≥5/group). (C) Absolute numbers of the indicated subpopulations among
CD11b+ cells in mice bearing EV, sgAhr or sgAreg KBP tumors (n≥5/group).
(D) Levels of indicated chemokines in cultured KBP cells expressing EV,
sgAhr or sgAreg vectors (n=4/group). (E) Positive correlation between CCL5,
CXCL1 and CXCL2 mRNA levels and the “ROS gene signature” in the TCGA
human Basal-like BC dataset. See Materials and Methods for details. (F)
Positive correlation between monocytic lineage cell count and the “ROS
gene signature” in the TCGA human Basal-like BC dataset. See Material and
Methods for details.
ERBB4. All these receptors promote intracellular signaling in
the form of homo- or heterodimers and upon binding to a
large spectrum of soluble ligands including EGF, epiregulin
(EREG), amphiregulin (AREG), epigen (EPGN), neuregulin
(NRG1/2/3/4), transforming growth factor alpha (TGFalpha) and
Heparin-binding EGF-like growth factor (HB-EGF) (25). In dif-
ferent cancer types, Erbb receptors and ligands are differentially
regulated during tumorigenesis and influence tumor progression
and response to therapies(26, 27).
To verify the specificity of Areg regulation by ROS in MEC,
we assessed the expression of different Erbb ligands in mouse
MEC treated with BSO. Of note, these cells mainly express Egfr,
Erbb2 and Erbb3 receptors (SI Appendix Fig. S2B). In these
cells, among all known Erbb ligands, BSO mainly induced the
expression of Areg (SI Appendix Fig. S2C). Areg mRNA upreg-
ulation by BSO appears to be ROS-mediated, since co-treatment
of human MEC with the antioxidant Trolox abolished both BSO-
induced ROS and the accumulation of this transcript (Fig. 2C,D).
Once translated, AREG is a membrane-bound protein whose
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Fig. 6. AhR-AREG axis is a promising therapeutic target in basal-like and
BRCA1-associated BC. (A) AhR expression levels in basal-like versus non-basal-
like BC cell lines included in the Cancer Cell Line Encyclopedia. See Material
and Methods for details. (B) Immunoblot of MDA-MB-468 cell line carrying a
wild-type (AhRwt) or deleted form of AhR (AhRko). Cells were left untreated
(Ctr) or exposed to 500μMBSO for 24h. (C) AREG mRNA levels in cells treated
as in (B). (D) Representative plot of tumor volume increase over time after
transplantation of MDA-MB-468 AhRwt and AhRko cells in the fat pad of
immune-compromised NOD-SCID female mice. (E) Sensitivity of MDA-MB-
468 AhRwt and AhRko cells to increasing doses of EGFR inhibitor, Erlotibin,
as measure by SRB growth assay. (F) Levels of secreted AREG in the media of
the indicated cell lines after treatment with the AhR inhibitor (CH-223191)
for 24h and represented as ratio to their respective AREG levels in control
(untreated) conditions. n=3. (G) Synergy scores for the AhR inhibitor, CH-
223191 (AhRi) and Erlotinib in the indicated BC cell lines as calculated using
the SynergyFinder web application (seeMaterial andMethods for details and
SI Appendix Fig. S7).
activation is regulated by release of its extracellular domain from
the membrane (28). Indeed, BSO treatment promoted AREG
release into the culture medium of MCF10A cells in a Trolox-
sensitive manner (Fig. 2E).
Next, we investigatedwhetherAhRwas involved in regulating
AREG expression. MEC isolated from female Ahrf/f mice were
infected with Cre-expressing adenovirus prior exposure to BSO.
Thus, BSO-induced upregulation of Areg was abrogated by loss
of transcriptional activity of AhR (Fig. 2F). This suggested that,
like Cyp1a1 (Fig. 1D), Areg might be a direct AhR transcrip-
tional target. Indeed, a putative XRE element (5′-G/T N T/G
GCGTG A/C-3′) was identified at -260bp from the ATG start
codon. COMMA-1D cells were treated with BSO for different
time points prior toChIP-qPCRassay. Compared to IgG antibody
control, AhR enrichment at Areg promoter started at 1h post-
treatment and gradually declined overtime (Fig. 2G).
Fig. 7. AhR-AREG axis defines a novel signaling pathway between cellular
intrinsic redoxmechanisms and surrounding TME. SeeDiscussion for detailed
description.
It is worth noting that MEC from Nrf2-/- mice accumulated
more Areg mRNA than MEC from Nrf2+/+ mice, ruling out that
the transcript increase is regulated by NRF2 (Fig. 2H).
In the TCGA dataset, AREG expression was also found to be
higher in BC with low levels of BRCA1 (Fig. 2I). Moreover, by
immunohistochemistry assay (IHC), AREG protein expression
was found to be significantly elevated in mammary pre-neoplastic
tissues of BRCA1 mutation carriers and in the corresponding
advanced tumors (Fig. 2J and SI Appendix S2D). Consistently,
in the TCGA BC dataset, AREG levels were also associated with
a high ROS score (Fig. S2K). Therefore, AREG is a novel tran-
scriptional target of AhR in MEC and its expression correlates
with AhR and ROS levels in human BC.
AhR-AREGaxis is required for BRCA1-associatedmammary
tumorigenesis
To characterize the functional involvement of the AhR-Areg
axis in basal-like and BRCA1-associated tumors, we took advan-
tage of a transplantable mouse primary mammary tumor cell line
(KBP) isolated from a mammary tumor arising in the K14cre
Brca1f/f Trp53f/f basal-like/TNBC mouse model (29). Mammary
tumors originating from KBP cells resemble spontaneous basal-
like/TNBC (30). Compared to normal MEC, the NRF2 target
Nqo1 was previously shown to be downregulated in mouse and
human Basal-like/TNBC tumors, as a consequence of defective
NRF2 function (12).However,Nqo1was still induced by exposure
to BSO in these cells, suggesting a coordinated transcriptional
control of this gene by NRF2 and AhR as shown in Fig. 1
(SI Appendix S3A). AhR targets Cyp1a1 and Areg were highly
expressed in KBP cells, as compared to normal MEC (Fig. 3A).
We then used CRISPR/Cas9 gene editing to delete mouse Ahr
and Areg in mammary tumor cells by transient transfection. KBP
cells with single guide (sg) RNA against Ahr (sgAhr) or Areg
(sgAreg) were maintained under selection for three days prior
to analysis in vitro or transplantation in vivo. The sgAreg and
sgAhr treatments of KBP cells did not affect their proliferation
prior transplantation (SI Appendix Fig. S3B) but did induce a
significant decrease in AREG and AhR proteins as compared
to cells transfected with control empty vector (EV) (Fig. 3B).
Notably, Ahr deletion also reduced AREG protein, confirming
that Areg is an AhR downstream target (Fig. 3B).
Next, we transplanted EV-, sgAreg- or sgAhr-transfected
KBP cells into the mammary fat pads of virgin female mice
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and monitored tumor growth until EV-treated tumors reached
humane endpoint (tumor volume=1cm3). Tumor development
in mice receiving either sgAreg- or sgAhr-transfected KBP cells
was significantly reduced compared to animals receiving EV-KBP
cells (Fig. 3C and SI Appendix Fig. S3C). Areg deletion almost
completely prevented the expansion of KBP tumor cells in vivo,
possibly as a result of a cell-autonomous requirement for AREG
in these cells. Indeed, Areg deletion in KBP cells impaired cell
growth in vitro as shown by Sulforhodamine B (SRB) assay over
a period of 12 days (SI Appendix Fig. S3D).
We confirmed that small tumors growing from sgAreg-treated
cells showed a significant reduction in AREG expression mea-
sured by IHC (Fig. 3D). sgAhr-treated cells had almost unde-
tectable expression of AhR that consequently affected AREG se-
cretion (Fig. 3 E,F). Then, we tested if AREG was the main Erbb
ligand to be regulated by AhR in KBP tumors. RNA sequencing
(RNA-seq) showed a similar expression profile of Erbb receptors
but higher levels of Areg, Hbegf and Nrg1 ligands were observed
in KBP tumors as compared to normal mammary gland tissue (SI
Appendix Fig. S3E). However, neitherHbegf norNrg1 expression
levels were affected by Ahr deletion as compared to Areg, further
underlying the existence of a specific AhR-AREG axis in these
tumors (SI Appendix Fig. S3F).
AhR-AREG axis regulates the phenotype and function of
macrophages in BRCA1-deleted mouse ma mary tumors
AhR and AREG are both expressed in innate and adaptive
immune cell populations to regulate immunity, inflammation and
tissue repair (31, 32). However, apart from a few studies (33-
35), the roles of these proteins in the TME is still uncertain.
Macrophages are the most abundant immune cells recruited
to the breast tumor site, where they become “tumor-associated
macrophages” (TAM). TAM have complex genetic and molecular
characteristics resulting in extraordinary plasticity and are par-
ticularly abundant in BC and present at all stages of progression
(36). To examine the characteristics of TAM, we first analyzed
macrophages resident in normal mammary tissue of virgin and
nulliparous FVB female mice. These cells typically expressed
integrin αMchain (CD11b), EGF-like module-containing mucin-
like hormone receptor-like 1 (F4/80), MER proto-oncogene tyro-
sine kinase (MerTK) and cluster of cifferentiation 64 (CD64)(37),
as well as the mannose receptor C type 1 (MRC1/CD206) (SI
Appendix Fig. S4A), which is also expressed by TAM (SI Ap-
pendix Fig. S5B) (38). KBP tumors showed a significant increase
in CD11b+F4/80+ macrophages as compared to mammary fat
pad (Fig. 4A). These macrophages expressed EGFR phosphory-
lation at tyrosine 106, suggesting activation of EGFR in TAM as
previously found in another tumor models(39, 40) (SI Appendix
Fig. S4C). Compared to control tumors, KBP tumors from sgAreg-
or sgAhR-treated cells had less CD11b+F4/80+ macrophages
with a surface marker profile of non-tumorigenic, tissue-resident
macrophage in the mammary fat pad (Fig. 4B,C).
Next, the relevance of TAM in BRCA1-deficient human BC
was quantified. IHC staining for CD163 showed that tumor-
associated AREG expression correlated with high density and
close proximity of macrophages in both pre-neoplastic (reduction
mammoplastic) and tumors from BRCA1 mutant carriers, (Fig.
4D and SI Appendix Fig. S4D). Collectively, these data postulate
a role of AhR-AREG signaling in attracting TAM into the breast
TME.
One well described function of TAM is to produce vascular
endothelial growth factor-A (VEGF-A), which facilitates angio-
genesis and metastasis (41). In vitro co-culture systems between
KBP cells and bone-marrow derived macrophages (BMDM)
showed that BMDM had a dramatic increase in Vegfa mRNA
expression after being in contact with tumor cells (Fig. 4E). These
changes contributed to an overall increase in the level of secreted
VEGF-A protein in the culture medium of KBP-BMDM co-
cultures (SI Appendix Fig. S4E). In contrast to BMDM,KBP cells
maintained a high basal level of VegfamRNA that did not change
after co-culture (SI Appendix Fig. S4F). VEGF-A production by
BMDM was mainly AREG dependent since deletion of KBP-
associated Areg strongly reduced Vegfa expression in BMDM in
co-culture systems (Fig. 4F). Furthermore, recombinant AREG
(rAREG) significantly increased Vegfa mRNA levels in BMDM
to a higher extent than ITE-mediated AhR activation (Fig. 4G).
We also discovered a significant increase in EGFR expression in
BMDM after co-culture with KBP cells, further supporting the
ability of BMDM to respond to AREG-mediated signaling (SI
Appendix Fig. S4G). Collectively, these data support the ability of
cancer-associated AhR and AREG expression to affect the den-
sity and tumor-supporting properties of TAM within mammary
TME. Corroborating these in vitro findings, we found that sgAreg
tumors had less CD31-positive endothelial cells, indicating a low
degree of tumor vasculature (Fig. 4H).
AhR-AREG axis influences myeloid cell recruitment in
BRCA1-deleted mouse mammary tumors
Normal mammary ductal genesis is characterized by the
epithelial cell-dependent recruitment of monocytes, which ma-
ture in situ into macrophage that provide critical support for
developing tissue (42). Similarly, during mouse BC tumorige-
nesis monocytes can be recruited by developing mammary tu-
mors, where they mature into pro-tumoral TAM characterized
by high CD11c expression (43). Furthermore, increases in pe-
ripheral blood monocytes is a key feature of human and mouse
malignancies, which correlates positively with TAM density in
human cancer (44). We found that KBP tumor-bearing animals
contained increased numbers of CD11b+ monocytes in the pe-
ripheral blood (Fig. 5A). In contrast, monocytes were signif-
icantly reduced in the peripheral blood of sgAreg and sgAhr
tumor bearing mice (Fig. 5B). Further stratification of these
cells revealed significantly reduced numbers of classical mono-
cytes (cMo; CD11b+Ly6-ChiLy6-G-CX3CR1+) in the blood of
sgAreg and sgAhr tumormice, with no significant changes in neu-
trophils (CD11b+Ly6-CintLy6-G+CX3CR1-) or patrolling mono-
cytes (pMo; CD11b+Ly6-Cint/loLy6-G- CX3CR1+) (Fig. 5C).
The recruitment and activation of monocytes and
macrophages are regulated by specific chemokines and cytokines
in the TME (45). Compared to MEC, KBP cells released
significantly higher levels of chemokines important for the
recruitment and activation of monocytes and macrophages such
as granulocyte-colony stimulating factor (G-CSF), chemokine
(C-X-C motif) ligand 1 (CXCL1), C-X-C motif ligand 5
(CXCL5), C-C motif chemokine ligand 2 (CCL2), C-X-C
motif ligand 2 (CXCL2) and C-C motif chemokine ligand 2
(CCL5) (SI Appendix Fig. S5A) (46). Interestingly, sgAreg and
sgAhr KBP tumor cells displayed significantly lower production
of all chemokines elevated in KBP control cells (Fig. 5D).
Treatment of sgAhr tumor cells with recombinant AREG
(rAREG) considerably rescued the levels of G-CSF, CXCL1,
CXCL5, CCL2, CXCL2 and CCL5 chemokines (SI Appendix
Fig. S6B). This result suggests that AhR expression affects
chemokine production through AREG modulation. Mouse data
were validated by analysis of human BC in the TCGA cohort.
Expression of CXCL1, CXCL2 and CCL5 chemokines correlated
positively with AhR and AREG expression and was high in BC
with low BRCA1 levels (SI Appendix Fig. S5C). Interestingly,
these chemokines were also increased in basal-like BC with
high ROS content (Fig. 5E), along with an elevated infiltration
of monocytic lineage cells (monocytes and macrophages) in
the TME (Fig. 5F). Our data show that AhR-AREG pathway
stimulates the recruitment of monocytic cells in the TME and
these changes correlate with high levels of cancer-associated
ROS in basal-like BC.
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AhR-AREG axis is a promising therapeutic target for human
BRCA1-associated BC
Then, we sought to test the oncogenic role of AhR in human
BC as previously performed in the mouse model. As found in
TCGA data analysis, AhR mRNA expression was more elevated
in basal-like versus non-basal-like BC cell lines (Fig. 6A). Next,
we a
MDA-MB-468 cells were CRISPR/Cas9 edited to obtain sta-
ble isogenic cell lines that were proficient (AhR wild-type, AhRwt)
or deficient for AhR (AhR knock-out, AhRko). Compared to
AhRwt, AhRko cells did not express AhR and consequently they
had a significant low level of AREG and CYP1A1 expression at
both basal level and upon exposure to BSO (Fig. 6B,C and SI
Appendix Fig. S6A). In these cells, AhR deletion dramatically
impaired their ability to both grow in vitro and form tumor in
the mammary fat pad of immunodeficient NOD-scid female mice
(Fig. 6D and SI Appendix Fig. S6B). Given the low levels of Areg
mRNA in AhRko cells, we tested their sensitivity to Erlotinib,
an EGFR tyrosine kinase inhibitor (47). AREG expression has
been associatedwith resistance toEGFR inhibitors in breast, lung
and colon cancers(48-51). Compared toAhRwt tumor cells,AhRko
cells were highly sensitive to EGFR inhibition as measured by a
standard 5-day SRB assay (Fig. 6E).
The above results prompted us to evaluate the therapeutic
value of interfering with AhR oncogenic function through the
use of a potent and specific AhR inhibitor (AhRi), namely CH-
223191(52). Treatment of a subset of basal-like BC cell lines
with 1μM CH-223191 for 24h significantly reduced secretion of
AREG, independently of the variability of AREG basal level in
these cells (Fig. 6F and SI Appendix Fig. S6C). In both MDA-
MB-468 and HCC1937, treatment with AhR inhibitor affected
AREG secretion in a dose-dependent manner and in the absence
of any external stimulus (SI Appendix Fig. S6D,E). Consistent
with this finding, CH-223191-treated HCC-1937 cells showed a
defect in the EGFR phosphorylation normally induced by incu-
bation in nutrient-rich culture medium as compared to untreated
cells or cells exposed to Erlotinib, an EGFR tyrosine kinase
inhibitor55 (SI Appendix Fig. S6F). These data suggest that AhR
inhibition by a chemical compound can affect EGFR activation.
Given the effect of AhR inhibition on AREG levels and
EGFR phosphorylation, we investigated whether the targeting
of AhR might synergize with Erlotinib treatment to curtail BC
cell growth.We seededMDA-MB-453, BT20,MDA-MB-468 and
HCC1937 cells in 96-well plates and treated them with various
combinations of Erlotinib and CH-223191. Erlotinib was used at
3-fold serial dilution starting at 25μM (5 dilutions total) while
CH-223191 was used at 3-fold serial dilution starting at 50μM
(9 dilutions total). First, we scored drug toxicity by calculating
cell density using the sulforhodamine B (SRB) colorimetric assay.
Then, we determined if there was any synergy in therapeutic activ-
ity betweenCH-223191 andErlotinib using SynergyFinder56. This
analysis revealed a high degree of therapeutic synergy between
Erlotinib and CH-223191 in cell lines with high EGFR expression
(BT20, MDA-MB-468 and HCC1937), but an antagonistic effect
where EGFR expression was low (MDA-MB-453) (Fig. 6G and
SI Appendix Fig. S7). These findings demonstrate a therapeutic
potential of targeting both the cell-extrinsic (secreted AREG)
and cell-intrinsic (intracellular AhR activation) components of
the AhR-AREG axis for the treatment of BRCA1-associated BC.
DISCUSSION
To date, most of the studies focused on AhR are linked to its
role as environmental sensor for dioxins and xenobiotics. Recent
work has elucidated a multitasking role of AhR in the control of
cancer cell survival and tumor-associated immune system func-
tions(53). The fact that AhR is chronically activated in many
tumor types, including BC, supports the premise that AhR might
be a promising drug target for anti-cancer therapies. However,
the benefits of targeting AhR is still under debate given the
contradictory observations that AhR is both pro-tumorigenic and
a tumor suppressor and the multitude of activities elicited by
different AhR ligands (14). In our work, analysis of human BC
data and the use of human and mouse BC models supports an
oncogenic role of AhR in Basal-like and BRCA1-associated BC.
In addition to controlling ROS, AhR stimulates transcription of
theEGFR ligandAREGand thereby activates EGFR signaling in
both normal andmalignantMEC. Interestingly, among all known
Erbb ligands, AREG is the main target of ROS-activated AhR
pathway. Thus, AhR ensures cell survival and proliferation by
coordinating an antioxidant response and activating the potent
tumor-promoting signaling pathway mediated by EGFR. Indeed,
AhR deletion by CRISPR/Cas9 gene editing dramatically im-
paired the in vivo growth of mouse and human TNBC cells.
Besides controlling cell intrinsic functions, AhR signal-
ing influences the infiltration and phenotypic properties of
macrophages in the TME. Tumor-infiltrating macrophages take
on a trophic role that facilitates angiogenesis, extracellular matrix
breakdown, and tumor cell motility, particularly in BC (41).
Conversely, human BC cells can educate macrophages to adopt
a tumorigenic and immunosuppressive phenotype that allows
the BC cells to avoid immune surveillance and continue their
invasion and growth (54). In our tumor model, we have found
that AhR and its downstream effector AREG regulate a cluster
of monocyte/macrophage-related chemokines that shape the im-
mune landscape of BRCA1-deficient mammary tumors, result-
ing in an increase in CD11b+F4/80+CD206+ TAM with a tu-
morigenic phenotype. Indeed, our co-culture of mouse BRCA1-
deficient tumor cells with BMDMprovides a clear demonstration
of the mutual communication between macrophages and tumor
cells in the expression ofVEGF-A and the control of tumor angio-
genesis. Analysis of TCGA human BC dataset have corroborated
the correlation between myeloid-related chemokines (CCL5 and
CXCL1/2) and expression levels of BRCA1, AhR and AREG.
Strikingly, the expression of these chemokines and the presence
of myeloid populations is associated with Basal-like BC with high
ROS content.
Overall, our observations suggest the followingmodel (graph-
ically summarized in Fig. 7). In basal-like/TNBC or BRCA1-
associated BC, genetic and metabolic alterations may lead to
chronic high ROS levels that trigger an increase in AhR protein
levels and transcriptional activity. In these conditions, AhR ac-
tivation counters ROS by promoting expression of antioxidant
genes but it also induces the expression of EGFR ligand, AREG.
Through the release of AREG and specific chemokines (G-CSF,
CXCL1/2/5 and CCL2/5) in the TME, AhR activation axis may
facilitate the recruitment of monocytes from blood vessels and
the activation of pro-tumorigenic and angiogenic TAM.
In conclusion, we have established a novel connection be-
tween tumor-intrinsic redox mechanisms and TME composition
in BC.Our in vivo work using aBrca1/Trp53-deletedmousemodel
reveals how both these aspects are prerequisites for tumor pro-
gression and maintenance. These observations provide valuable
insights into the multifactorial oncogenic activity of AhR and
may form the basis of a better tailored future drug development
against one of the most aggressive and challenging type of BC.
Materials and Methods
Mice
K14cre BRCA1f/f p53f/f (KBP) mice were provided by Dr. J. Jonkers
(NKI, Amsterdam, The Netherlands) and were on the FVB background. KBP
tumor cells were obtained and used for in vivo transplantation studies as
described(30). NRF2-/- mice were kindly provided by Dr. P. Ohashi (Princess
Margaret Cancer Centre, Toronto, Canada) and were on the C57/B6 back-
ground. AhRf/f mice were purchased from The Jackson Laboratory (stock
no: 006203) and were on a mixed background. For mouse and human tu-
mor transplantation studies, FVB and immune-deficient NOD-SCID recipient
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female mice were 8-10 week old and were purchased from The Jackson
Laboratory. All mice were maintained and handled according to protocols
approved by the Animal Care and Use Committee of the University Health
Network (UHN; Toronto, Canada).
Cell lines and treatments
Mouse COMMA-1D cells (originally provided by S. Muthuswamy, On-
tario Cancer Institute, Toronto, Canada), primary mouse MEC, and KBP cells
were cultured in DMEM/F12 medium containing 10% FBS (Thermo Fisher
Scientific), L-glutamine, 1 µg/ml hydrocortisone (Sigma), 5 µg/ml insulin
(Sigma), and 5 ng/ml epidermal growth factor (EGF, Sigma). Human MCF10A
cells (ATCC) were cultured in DMEM/F12 medium supplemented with 5%
horse serum (Thermo Fisher Scientific), 20 ng/ml epidermal growth factor
(EGF), 0.5 µg/ml hydrocortisone, 100 ng/ml cholera toxin (Sigma), 10 µg/ml
insulin, and penicillin-streptomycin (Pen-Strep, Thermo Fisher Scientific).
Human breast cancer cell lines (ATCC) were cultured under strain-specific
conditions according to ATCC recommendations.
Oxidative stress was induced for various times by exposing cells to
medium containing 50 µM or 200 µM buthionine sulfoximine (BSO, Sigma).
For ROS scavenging, BSO-exposed cells were co-treated with 250 µM Trolox
(EMD Millipore). MEC were starved in 0.5% FBS and nutrient-free medium
for 24h and then treated in the same medium with 50ng/ml recombinant
AREG from R&D Systems (262-AR-100) and harvested after 24 hr. The AhR
antagonist CH-223191 (Sigma) was applied to cell cultures at 1μM, 5μM and
10μMfor 24h (AREGmeasurement by ELISA), 900nM (analysis of EGF receptor
phosphorylation in HCC1937) or different doses for 5 days (drug screening).
The tyrosine kinase inhibitor, Erlotinib, was administrated to HCC1937 cell
line at 600nM for analysis of EGF receptor phosphorylation by Western Blot.
Isolation of primary murine mammary epithelial cells (MEC)
Primary murine MEC were isolated from 8-10 week old virgin female
mice as previously described(12). MEC were cultured in serum-free medium
for 48 hr to kill stromal fibroblasts and seeded (5x105) in 6-well plates for
experiments. In the case of AhRf/f mice, MEC (1x105) were seeded in 6-well
plates and infected overnight with pre-packaged, ready-to-use adenovirus
expressing Cre recombinase (Vector BioLabs, PA, USA). Cells were processed
for analysis 48 hr after infection.
Preparation of murine bone marrow-derived macrophages (BMDM)
Whole bone marrow was harvested from 10-12 week old female mice
by flushing Hanks' Balanced Salt Solution (HBSS) through femurs and tibias
using a 27-gauge needle (BD Biosciences). Following red blood cell lysis, cells
were cultured in 10% RPMI in 10cm plates overnight. Non-adherent cells
were collected and reseeded in petri dishes in medium containing 20 ng/ml
murine macrophage colony-stimulating factor (M-CSF; Peprotech). After 3
days of culture, cells were provided with fresh medium containing 20ng/ml
M-CSF. Macrophages were harvested on day 4.
For co-culture experiments, BMDM (1x106) were seeded in triplicate in
6-well plates and incubated with or without KBP cells (2.5x105 cells/well).
Cells were harvested 48 hr later using enzyme-free cell dissociation medium
(Millipore) and either processed for flow cytometric analysis or sorted as
described in Flow Cytometry and Sorting.
Mouse and human tumor induction and treatment
KBP (3x105) or MDA-MB-468 (0.5x106) cells were transplanted into #4
mammary gland fat pads of syngeneic FVB or NOD-SCID female mice (10
weeks old). Diameters of developing tumors were measured in duplicate
using digital calipers starting on day 14 (KBP) or day 30 (MDA-MB-468)
post-transplantation when tumors became palpable. Tumor volume (mm3)
was calculated as ½(width2 * height). Tumor diameters were measured and
volumes calculated as above two times per week.
Mouse mammary tumor dissociation for FACS analysis
Tumors were resected from #4 mammary fat pads of transplanted mice,
cut into 2-3mm2 pieces, and placed into a C-tube (Miltenyi Biotech) contain-
ing 5 ml Iscove's Modified Dulbecco's Medium (IMDM) supplemented with
10% FBS, 2 mM L-glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin,
0.05 mM β-mercaptoethanol, 0.26 U/ml Liberase TM (Sigma), and 20 U/ml
DNase I (Sigma). Tumors were mechanically processed using a gentleMACS
Octo Dissociator with Heaters (Miltenyi Biotech). Processed samples were
filtered once through a 100 µm cell strainer (Falcon), and the corresponding
C-tubes were rinsed with 5 ml cold IMDM and passed through the same
strainer. Cells were filtered once using a 70 µm strainer (Falcon), followed
by a 40 µm strainer (Falcon). Filtered samples were collected in 15 ml
Falcon tubes and centrifuged at 1250 RPM for 8 min at 4°C. Pellets were
incubated with red blood cell lysis buffer for 7 min at room temperature
(RT), and then centrifuged at 1250 RPM for 8 min at 4°C before resus-
pension in PBS-/- containing 1% bovine serum albumin (BSA) plus 2 mM
ethylenediaminetetraacetic acid (EDTA). Cell suspensions were subjected to
fluorescence-activated cell sorting (FACS)/flow cytometry as described below.
Flow cytometry and cell sorting
Flow cytometric analyses of tumor-associated macrophages (TAM) and
BMDM were performed using the following Abs: anti-CD49f-AF488 GoH3,
anti-CD45.1-AF700 A20, anti-CD11b-Pacific Blue M1/70, anti-F4/80-PE BM8,
anti-CD206-APC C068C2, anti-CD11c-APCCy7 N418, and anti-MHCII-PECy7
M5/114.15.2 (all from BioLegend). For FACS experiments, macrophages were
identified as CD49flo/-CD45+CD11b+F4/80hi and sorted to >95% purity into
10% RPMI at 4-8°C. BMMΦ were further processed for RNA extraction (see
below), while TAM were seeded into 96-well flat-bottom plates at 2x105
cells/well. For flow cytometric analysis of resident macrophages in mammary
glands of naïve FVB mice, the additional Abs anti-MerTk-PE 108928 (R&D
Systems) and anti-CD64-PE X54-5/7.1 (BioLegend) were applied.
For analysis of peripheral blood monocytes, blood (15 μl) was collected
from the tail veins of live mice into a heparinized capillary tube, followed
by transfer into a 5 ml polystyrene tube containing 100 μl PBS-/- plus 20
mM EDTA. Peripheral blood samples were stained directly with anti-Ly6C-
PE HK1.4, anti-Ly6G-APCCy7 1A8, and anti-F4/80-FITC BM8 (BioLegend) Abs
in combination with the Abs described above.
All flow cytometry samples were blocked for a minimum of 10 min
in 1:100 anti-CD16/CD32 2.4G2 (eBioscience) containing 1:200 DNase I
(protease-free, Roche) prior to staining in PBS-/- containing 1% BSA plus 2
mM EDTA. After blocking, Abs were added at appropriate dilutions and cells
were stained for 30 min on ice. Dead cells were excluded by adding 5 μl 7-
AAD (BioLegend) during the last 10 min of surface staining. Cells were then
washed and either sorted on an Astrios FACS Instrument (Beckman Coulter),
or analyzed using a Fortessa Instrument (BD Bioscience) and FlowJo software
(Tree Star, Inc.).­­
For flow analysis of phosphorylated EGFR, tumors were dissociated
according to mouse mammary tumor dissociation method. 106cells were
suspended in 0.5 ml PBS-/- and fixed with 0.5 ml of 4% formaldehyde (final
concentration 2%) for 10 min at 37°C. Cells were washed by centrifugation
with PBS-/- containing 1%BSA and 2mMEDTA prior stainingwith anti-CD49f
(AF488 GoH3; 1/200), anti-CD45.1 (AF700 A20; 1/400), anti-CD11b (Pacific
BlueM1/70; 1/400) and anti-F4/80-PE (BM8; 1/400) for 30min on ice. Cells were
then washed twice and permeabilized by adding ice-cold Perm Buffer II (BD)
with gently vortexing. Cells were incubated for 30 min on ice and washed
twice. Cells were then suspended in 100μl of primary phospho-EGF Receptor
(Tyr1068) antibody (D7A5, 1:1600, Cell signaling) and incubated for 1h on
ice. Cells were washed twice and then resuspended in 100μl of secondary
antibody (goat anti-rabbit APC coniugated, ThermoFisher Scientific, 1/1000)
and incubated for 1h on ice. Cells were washed twice and analyzed at
Fortessa Instrument (BD Bioscience) and data were processed with FlowJo
software (Tree Star, Inc.).
CRISPR/Cas9 gene-editing
For CRISPR/CAS9 gene-editing studies in mouse and human cells, single
guide RNAs were evaluated using two different online CRISPR design tools:
theMIT online CRISPR Design Tool (http://crispr.mit.edu/), and the Zinc Finger
Consortium Tool (http://zifit.partners.org/ZiFiT/CSquare9Nuclease.aspx). To
minimize potential off-target mutations, we selected highly specific guide
RNA sequences which were predicted to have zero potential off–targets;
even after 3 mismatches in the 20 nucleotide sgRNA sequence. The following
oligos were used to synthetize mouse guide target sequences: mouse AhR,
forward primer 5’-CACCGCTAGCGTCAGCTACCTGA-3’ and reverse primer
5’-AAACRCAGGTAGCTGACGCTGAGC-3’; and mouse Amphiregulin, forward
primer 5’-CACCGGTGGACTTGAGCTTTCTGT-3’ and reverse primer 5’-AAACA-
CAGAAAGCTCAAGTCCACC-3’. For CRISPR/CAS9 gene-editing of human AhR
in MDA-MB-468, an sgRNA targeting human AhR exon1 (NC 000007.14) was
designed. The following guide oligos were designed to express the sgRNA:
forward primer 5’- CACCGTCACCTACGCCAGTCGCAAG -3’ and reverse primer
5’- AAACCTTGCGACTGGCGTAGGTGAC -3’. In all cases, the annealed double-
stranded guide oligo was cloned into the BbsI cut puromycin-modified
version of vector pX330 (Addgene plasmid # 42230). To obtain a stable MDA-
MB-468 line carrying AhR deletion, the px330-PURO hAhR-sgRNA plasmid
vector was transfected into cells using Lipofectamine 3000 (Thermofisher),
followed by brief selection pressure in 1ug/ml puromycin for 48 hours,
and isolation of resistant individual clonal cell lines after 2 weeks. A 748
bp genomic PCR amplicon spanning the human AhR exon1 CRISPR/CAS9
sgRNA target sequence was amplified using the forward primer: 5'-CAC-
GCCACTGTCCCGAGAGGACGCAGGTG- 3', and reverse primer: 5'-TATGAGC-
GCAACACAAAGCCAGTTGGTGG- 3'. Direct DNA sequencing of the human
AhR exon1-spanning genomic DNA PCR amplicon was performed using the
sequencing primers: forward 5'- AGTGGTCCCAGCCTACAC -3' and reverse
5'-GCTGTCAACAAATCAGGACC- 3'. Human AhR exon1 CRISPR/CAS9 frame-
shift modifications on each allele was verified by analysis of DNA sequence
chromatograms. Human and mouse AhR knock-out was further verified and
validated using RT-PCR of downstream targets or Western blotting with AhR
specific antibody (BML-SA210-0025, Enzo Life Sciences).
siRNA and sgRNA cell transfection
COMMA-1D, KBP and MDA-MB-468 cells (1x105) were seeded into 6-
well plates and transfected overnight with specific plasmids plus Lipofec-
tamine 3000 (Life Technologies). For studies of AhR and NRF2 combinatorial
downregulation, COMMA-1D cells were first transfected with empty vector
or empty vector containing AhR single guide RNA, then kept in mediumwith
1 µg/ml puromycin (Wisent Bio Products) for 2 days prior transfection with
mouse NRF2 siRNA (50pmo, Thermo Fisher Scientific). KBP transfected cells
were cultured in medium with 1 µg/ml puromycin for 72 hr prior to injection
into #4 mammary fat pads of syngeneic female FVB mice. MDA-MB-468 cells
were cultured andmaintained inmedium containing 1 µg/ml puromycin until
expansion of stable resistant clones.
Cell proliferation measurement
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KBP cells expressing empty vector and sgRNA against mouse Areg and
AhR were analyzed for proliferation by using 488 EdU Click Proliferation Kit
(BD Biosciences), accordingly to manufacture’s guidelines.
Apoptosis measurement
Apoptosis was evaluated by Annexin V/7-AAD staining. In brief, cells
were collected and stainedwith FITC-conjugatedAnnexin V and 7-AAD for 15
min at room temperature in 10× binding buffer. All reagents were purchased
from BD Biosciences. Cells were analyzed by a FACSCalibur flow cytometer
immediately after staining.
Cell growth measurement
KBP cells were transfected with sgAhr, sgAreg or EV as described above.
Positive selection was applied using 1ug/ml puromycin for 48 hours. Cells
were then resuspended, counted and plated in 6-well plates. Cells were
fixed at the indicated time points for subsequent SRB assay analysis. Time
points were seeded in triplicate. Cell number was assessed indirectly by
using the Sulforhodamine B (SRB) colorimetric assay (Sigma) according to
the manufacturer’s recommendations.
Drug sensitivity screening
Human breast cancer cell lines were seeded at different concentrations
accordingly to the cell line to obtain 30% confluency in 96-well plates in
triplicate. After 24 hr, cells were treatedwith Erlotinib at 3-fold serial dilution
starting at 25฀M (5 dilutions total) and/or CH-223191 at 3-fold serial dilution
starting at 50฀M (9 dilutions total). Cells were maintained in culture for 5
days before calculating cell density using the sulforhodamine B (SRB) colori-
metric assay (Sigma) according to the manufacturer’s recommendations. Cell
density was calculated using the SoftMax Pro software (Molecular Devices).
Immunoblotting
Mouse and human MEC were collected post-treatment and lysed in
RIPA buffer. Protein content was measured using the Bio-Rad Protein Assay
(Bio-Rad). Samples were resuspended in 4X Bolt LDS Sample Buffer (Life
Technologies) and incubated at 70°C for 5 min before loading on precast
BOLT 4-12% Bis-Tris Plus gels (Life Technologies). Immunoblotting was per-
formed using a standard protocol and primary Abs recognizing the following
proteins: Aryl hydrocarbon Receptor (BML-SA210-0025, Enzo Life Sciences),
vinculin (SPM227, Abcam), amphiregulin (16036-1-IP, Proteintech), total EGF-
receptor (#4267, Cell Signaling), phospho-EGF receptor (Tyr1068) (#2234, Cell
Signaling), alpha-tubulin (T5168, Sigma) and actin (A2066, Sigma-Aldrich).
Primary Abs were visualized using anti-mouse and anti-rabbit ECL HRP-
conjugated secondary Abs (Amersham). Membranes were developed for
chemiluminescent detection and images were acquired with GelCapture
Software using MicroChemi 2.0/4.2 (FroggaBio).
ELISA and cytokine profiling
Detection of mouse and human amphiregulin in culture supernatants of
mouse and human MEC and human breast cancer cell lines was performed
using theMouse andHumanAmphiregulin DuoSet ELISA Kit (R&D) according
to manufacturer’s protocol. Absorbance was determined at 450nm on a
FlexStation 3 plate reader (Molecular Devices). Cytokine profiling was con-
ducted using the Cytokine Array-Mouse Cytokine Antibody Array kit (Abcam)
according to manufacturer’s instructions. Membranes were developed for
chemiluminescent detection and images were acquired with GelCapture
Software using MicroChemi 2.0/4.2 (FroggaBio).
RT-PCR
RNA was isolated using the Nucleospin RNA Plus kit (Macherey-Nagel)
and reverse-transcribed using the iScript cDNA synthesis kit (Bio-Rad) accord-
ing tomanufacturers’ instructions. Quantitative RT-PCRwas performed using
SYBR Green primers (Applied Biosystems). Mouse ribosomal protein S9 (rps9)
and human ribosomal protein S18 (rps18) were used as housekeeping genes
to determine relative mRNA expression. All primer sequences are described
in SI Appendix, Table S1.
RNA sequencing
Total RNA was isolated from MEC and KBP mammary tumors using
the Nucleospin RNA Plus kit (Macherey-Nagel). 2ug of RNA were assessed
for quality control using the Agilent Bioanalyzer prior to library construc-
tion. RNA deep sequencing was performed with the Illumina HiSeq 2000
sequencing system at Princess Margaret Genomic Centre (Toronto, Canada).
Processed sequence data were obtained as .fastq files along with FASTQC
data. The regularized log-normalized (rlog) expression values were plotted
by transforming the count data to the log2 scale according to the method
previously described by Love et al.(55).
Chromatin immunoprecipitation
ChIP was performed in COMMA-1D cells as previously described (56)
with the following modifications: AhR protein (4 µg; Enzo Life Sciences) was
prebound to Protein A and G Dynabeads (Life Technologies) for 6 hr. DNA
fragments were purified with the MinElute PCR purification kit (Qiagen) and
processed for quantitative PCR analysis according to the manufacturer’s pro-
tocol. Fold enrichment was calculated over input. The statistical significance
of differences in enrichment was calculated using the unpaired Student t-
test. A complete list of PCR primers appears in SI Appendix, Table S2.
ROS measurement
To measure intracellular ROS, cells were incubated with 300 nM CM-
H2DCFDA (DCF-DA, C6827, Invitrogen) for 10 min at 37°C. DCF-DA fluores-
cence was analyzed by flow cytometry using a FACS Canto instrument (BD
Biosciences) and FlowJo software.
Immunocytochemistry (ICC)
COMMA-1D were seeded onto glass coverslips in 12 well plates in
triplicates (1x105/well). Cells were treated with BSO at 200μM for 1h. Cells
were fixed with paraformaldehyde (2% PAF) at room temperature for 10min
and then washed with PBS1X twice. Cells were incubated with Blocking
buffer containing 10% FBS and 0.05% Triton in PBS1X at room temperature
for 1h. Primary antibody (Aryl hydrocarbon Receptor (BML-SA210-0025, Enzo
Life Sciences) was diluted at 1/100 in Blocking buffer and applied at room
temperature for 1h. Cells were washed with 2% FBS Blocking buffer three
times prior incubation with secondary antibody (goat anti-rabbit Alexa Fluor
568, ThermoFisher Scientific) at 1/1000 at room temperature for 1h. Cells
were washed with 2% FBS Blocking buffer three times and then stained
with DAPI (0.5ug/ml in PBS1X) at room temperature for 5min. Coverslips
were rinsed in water and mount with VectaShield (50ul/coverslip, Vector
Laboratories). Images were acquired with a fluorescence microscope (Zeiss
AxioImager M1 equipped with Hamamatsu ORCA Flash4 camera) using Zeiss
Zen software and processed with Adobe Photoshop CS5. Data were reported
as percentage of cells with AhR positive nuclear staining per total number of
cells (n=100).
Statistical analyses of mouse and human cell line data
Data were reported in bar graphs as the mean or median ± standard
error of the mean (SEM), with p-values calculated using Student’s t-test
(*≤0.05, **≤0.01, ***≤0.001). The mean was calculated based on a minimum
of n=3 replicates in each experiment, and each experiment was performed
at least 3 times. Data were analyzed either by Microsoft Excel or GraphPad
Prism 7.
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SI Appendix Material and Methods (Analysis of human samples) 
Immunohistochemistry (IHC)  
Women carrying BRCA1/2 mutations were recruited by the Genetic Counseling Unit of 
the Catalan Institute of Oncology, L’Hospitalet (Barcelona). The IDIBELL’s Ethics 
Committee approved the study protocol and written informed consent was obtained from 
all participants. Control breast tissue samples were acquired from anonymous 
premenopausal women undergoing reduction mastectomy at the University Hospital of 
Bellvitge, IDIBELL. IHC was performed as previously described(12). Tissue samples were 
incubated overnight at 4ºC with anti-amphiregulin primary Ab (16036-1 AP, Proteintech) 
at a dilution of 1:100. Specimens were viewed with a brightfield microscope (Leica 
DM2500 equipped with Micropublisher 3.3-QI imaging camera) using Q-Capture Pro 
Software and processed with Adobe Photoshop CS5.  
For identification of human CD163-positive macrophages in human breast cancers, IHC 
was performed with CD163 primary antibody (MCA1853, Bio-Rad) as previously 
described(57). AREG positive regions were identified by pre-segmenting the images at 
10x magnification using multiresolution segmentation in Definiens DeveloperXD (scale = 
800, shape coefficient = 0.4, compactness coefficient = 0.1) and classified based on the 
object’s mean intensity, the number of standard deviations from the image mean in AREG 
stain channel, its relative brightness compared to neighbour objects, and with shape 
morphometrics. AREG positive regions were grown by 20 pixels (~26um) up to 100 pixels 
in order to fill gaps between very close AREG positive objects, to include immediately 
adjacent stroma, and to combine small regions of AREG positive epithelium that, in a 3D 
setting, would have come from the same structure. AREG negative regions were 
identified as any regions which was not AREG positive or one of the pixel-distance bins. 
Any misclassified regions were manually corrected. Images were captured with Olympus 
IX81 fluorescence microscope and processed with ZEN imaging software, CZI. Data were 
analyzed by GraphPad Prism 7.  
For IHC staining of mouse KBP tumors, tissue specimens were incubated with primary 
Abs to detect amphiregulin (16036-1 AP, Proteintech), F4/80 (MCA497GAR, Bio-Rad), 
and CD31(AB28364, Abcam). For amphiregulin, we applied the same conditions as for 
human breast cancer specimen as described above. For F4/80 staining, antigen retrivial 
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for perfomed with Proteinase K (PK) treatment at 37°C for 10 min. The primary Ab was 
prepared in 5% rabbit serum with 0,2% Triton X-100 at a dilution of 1:200 overnight at 
4ºC. Secondary Ab (Vector labs BA-4001) was incubated for 30 min at a dilution of 1:400. 
For IHC staining of CD31 positive cells tissue samples were incubated in 10mM Na Citrate 
(pH6) solution. The primary Ab was diluted at 1:50 dilution in DAKO Protein block and 
incubated for 45 minutes at room temperature. Secondary Ab (Jackson Labs) was diluted 
1:400 and incubated for 45 minutes. In both cases, slides were digitized using a 
Nanozoomer2.0 HT-Hamamatsu (Olympus). An image analysis protocol (APP) was 
developed using Visiopharm software (Visiopharm, Denmark) to identify the area of IHC 
staining positive for F480 and CD31. A ratio of positive expression to region of interest 
was then calculated for each test group. In both human breast cancer and mouse tumor 
specimen, DAPI was used as nuclear staining. 
Analysis of human breast cancer datasets 
The results published here are partly based upon data generated by TCGA managed by 
the National Cancer Institute (NCI) and the National Human Genome Research Institute 
(NHGRI). Information about TCGA can be found at http://cancergenome.nih.gov. HR-
deficient BC cohort was defined by using TCGA breast cancer RNAseq data and somatic 
mutations after being obtained following approval by the Data Access Committee (project 
#11689). Mutational signatures were defined using the R mut Signatures package(58). 
The GSEA tool was run with default values for all parameters. 
Gene expression differences stratified according to BRCA1 mRNA level were analyzed 
using preprocessed and normalized RNA-seq and microarray expression TCGA data 
(downloaded from the GDC data portal on 2016-04-22). For each gene, a logistic 
regression analysis was implemented to assess its association with the expression level 
of BRCA1, categorized in tertiles. Unadjusted and adjusted (with covariates of ERBB2, 
ESR1, and PGR expression) models were used, which provided similar estimations. 
Gene expression correlations were computed using Pearson’s correlation coefficient, and 
p-values indicated the probability of independence. Data were normalized to log2 
standard TCGA normalization. Rosetta microarray-derived gene expression data along 
with BRCA1 mutation status from the Van’t Veer cohort were downloaded from 
http://www.rii.com/publications/default.htm(59). Because the expression profiles obtained 
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were log-ratio data, no further normalization was performed. Comparison of AhR, 
CYP1A1, and CYP1A2 expression levels in BRCA1-mutated versus wild-type breast 
tumors was performed using a two-tailed Mann-Whitney U test and GraphPad Prism 
Software. 
PAM50 calls annotated in clinical data were used to identify primary breast tumors of the 
basal subtype (n=141) which were segregated into quartiles based on AREG mRNA 
levels. Candidate gene expression levels were then compared in tumors in the top and 
bottom quartiles. Expression profiles were subjected to single sample gene set 
enrichment analysis (ssGSEA) using the Broad’s GenePattern tool to derive individual 
tumor enrichment scores for a panel of MSigDB gene-sets corresponding to the cellular 
response to oxidative stress 
(http://software.broadinstitute.org/cancer/software/genepattern/)(60, 61). The 
“Chuang_oxidative_stress_response” gene set (ROS up-regulated genes only) displayed 
the greatest variance in ssGSEA enrichment scores across tumors and was chosen for 
subsequent analysis. Tumors were classified into quartiles based on their ssGSEA scores 
for this gene-set. AhR, CYP1B1, AREG, CCL5, CXCL1 and CXCL2 expression levels  
were then compared between tumors in the top and bottom quartiles, representing those 
with high and low responses to oxidative stress, respectively. All two-group statistical 
comparisons of gene expression levels were performed using a two-tailed Mann-Whitney 
U test and GraphPad Prism Software. 
The immune cell content in tumors was inferred using the Microenvironment Cell 
Populations-counter method (62). These analyses and PCC computations were 
performed in R software. 
The AHR and AHR-ARNT target gene sets were obtained from the TRANSFAC 
database(63). The expression signature scores were computed using the ssGSEA 
algorithm with standard parameters and using all genes included in each set.  The 
Pearson’s correlation coefficients and p-values were computed in R. 
Cancer Cell Line Encyclopedia was used to investigate the expression of AhR in human 
breast cancer cell lines(64, 65). The cell lines were grouped into basal-like and non-basal-
like based on the method previously described(66).  
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SI Appendix Figure Legends 
Figure S1. AhR expression and activation in NRF2-deleted cells and BC with high 
ROS levels. (A) AhR mRNA levels in human MCF10A cells left untreated (Ctr) or treated 
with 200μM BSO for 24h. (B) Representative images of immunofluorescence assay in 
COMMA-1D cells treated with 200μM BSO for 1h or left untreated (Ctr). Blue=nuclear 
staining with Dapi, Magenta=AhR staining. The cells contained in dashed rectangles are 
reported in Figure 1D as example of scoring criteria of low/undetectable or positive AhR 
nuclear signal. Scale bar=20µm. (C) Expression levels of Ahr exon2 in mouse MEC that 
were isolated from Ahrf/f mice, infected with cre-expressing (+cre) or empty vector (-cre) 
adenoviruses and then left untreated (Ctr) or treated with 50 μM BSO for 24hr before 
analysis. (D) Nrf2 mRNA levels of mouse MEC isolated from Nrf2-/- or Nrf2+/+ mice. (E) 
AhR mRNA levels of mouse MEC as in (D). (F, G) Hmox1 and Nqo1 mRNA levels of 
mouse MEC as in (D). (H) Nrf2 mRNA levels of COMMA-1D cells transfected with non-
targeting (scramble, Scr) or mouse Nrf2 (siNrf2) siRNA oligos. Cells were analyzed at 48h 
post-transfection. (I) mRNA analysis of AhR-target Cyp1a1 in COMMA-1D cells that were 
transfected with single guide RNA against mouse AhR (sgAhR) and siRNA oligos specific 
for mouse Nrf2 (siNrf2) and then subjected to BSO (200µM) for 24h. Cells manipulated 
with empty vector (EV) and non-targeting (scramble, scr) siRNA were used as control. 
n=3/group. (J) mRNA levels of Ahr, CYP1A1 and CYP1A2 in the Van’t Veer human BC 
dataset with tumors segregated by BRCA1 genotype: Wild-type, n=21; Mutated, n=18. 
(K) Inverse correlation between AhR or CYP1B1 expression with low or high BRCA1 
mRNA levels in the TCGA human BC dataset.  
Figure S2. Expression of AREG in normal and malignant mammary epithelial cells 
and analysis of Erbb receptors and ligands. (A) Immunoblot showing AREG protein in 
MCF10A cells that were left untreated (Ctr) or treated with 200μM BSO for 24hr or 48hr. 
(B) mRNA expression of mouse Erbb receptors as indicated in COMMA-1D cells. n=3. 
(C) mRNA expression of mouse Erbb ligands as indicated in COMMA-1D cells that were 
left untreated or subjected to 200mM BSO for 24h. n=3/group. (D) Quantification of AREG 
	 5	
expression in BRCA1 wild-type reduction mammoplasty from healthy women used as 
controls, prophylactic mastectomy specimen in women heterozygous for a BRCA1 
mutation (BRCA1 mutant), and human BRCA1 mutant basal/TNBC breast tumours as 
shown in Figure 2J. 
Figure S3. AhR-AREG axis has a pivotal role in BRCA1-associated tumorigenesis. 
(A) mRNA levels of Nqo1 in KBP cells that were left untreated or treated with 200mM BSO 
for 24h. n=3/group. (B) Representative flow plots of DNA synthesis in KBP cells that were 
transfected with empty vector (EV), or vectors expressing sgAhr or sgAreg constructs, 
and examined at 24hr or 48hr after puromycin selection. (C) Representative images of 
EV-, sgAhr- or sgAreg- expressing KBP tumors (red arrows) in the mice on day 35 post-
transplantation. (D) Growth curve of EV-, sgAhr- or sgAreg- expressing KBP cells by SRB 
colorimetric assay at different time points. (E) RNAseq data obtained from RNA deep 
sequencing of mouse MEC and KBP tumors (n=3/group). The lower and upper hinges 
correspond to the first and third quartiles (the 25th and 75th percentiles). The upper 
whisker extends from the hinge to the largest value no further than 1.5 * IQR from the 
hinge, and the lower whisker extends from the hinge to the smallest value at most 1.5 * 
IQR of the hinge (where IQR is the inter-quartile range, or distance between the first and 
third quartiles). (F) mRNA levels of Erbb ligands (Areg, Hbegf, Nrg1) in EV and sgAhR 
KBP tumors. n=3-5/group. 
Figure S4. Analysis of tumour-infiltrating macrophages and bone marrow derived 
macrophages. (A,B) Representative plots describing the gating strategy used to 
characterize macrophages in the mammary fat pad of virgin and nulliparous FVB female 
mice and KBP mammary tumors. (C) Histogram of phosphorylated EGFR (p-EGFR) 
signal in macrophages that were positive for CD11b and F4/80 surface markers 
(CD11b+F4/80+) in KBP tumors. Staining with isotype control was used to assess the 
specificity of the signal. (D) Left, representative image of the concentric regions “grown” 
from the area and at a distance spanning from 20pix to 100pix. Right, Quantification of 
CD163+ macrophages at different distances from an AREG-positive tumour area. (E) 
ELISA measurement of secreted VEGF-A protein in the medium of BMDM cultured alone, 
or after co-culture with KBP cells for 24hr (n=3/group). (F) Vegfa mRNA levels in KBP 
	 6	
cells alone (-) or after co-culturing with BMDM for 24 hr. (G) Egfr mRNA analysis in BMDM 
cultured alone, or after co-culture with KBP cells for 24hr (n=3/group). 
 
Figure S5. Analysis of monocyte- and macrophage-related chemokines in 
BRCA1/p53-deleted mammary tumors. (A) Levels of the indicated chemokines in the 
culture medium of mouse MEC or KBP cells after 24hr culture (n=4/group). (B) Levels of 
the indicated chemokines in the culture medium of EV- or sgAhr-expressing KBP cells 
treated for 24hr with recombinant AREG (rAREG) at 50ng/ml. (C) Levels of CXCL1, 
CXCL2 and CCL5 mRNAs in TCGA BC grouped accordingly to low or high expression of 
BRCA1, AhR or AREG as indicated on the x-axis (n=1102).  
 
Figure S6. Effect of AhR loss-of-function in human breast cancer and mouse 
mammary tumors. (A) mRNA levels of CYP1A1 in MDA-MB-468 cell line carrying a wild-
type (AhRwt) or deleted form of AhR (AhRko). Cells were left untreated (Ctr) or exposed to 
500mM BSO for 24h. (B) Growth curve of MDA-MB-468 AhRwt and AhRko cells for 4 days 
as measured by Tripan-blue exclusion assay. (C) Levels of secreted AREG in the media 
of the indicated cell lines that have been seeded and maintained in growth factor-rich 
media for 24h. (D,E) AREG levels in the culture medium of MDA-MB-468 and HCC1937 
cell lines treated with increasing dose of the AhR inhibitor (AhRi), CH223191. (F) 
Immunoblot showing total EGFR, phosphorylated EGFR (P-EGFR) and AhR proteins in 
HCC1937 cells that were left untreated (Ctr) or treated with Erlotinib (E; 600nM) or AhRi 
(900nM) for 24 hr.   
Figure S7. Sensitivity of breast cancer cell lines to AhR and EGFR inhibition. 
Synergy score plots as determined by analyzing data from 5-day SRB growth using the 
SynergyFinder web application. Red and green colors indicate the most synergistic or 
antagonist areas, respectively.  
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Supplementary Table 1: Primers used for qRT-PCR (m=mouse) 
	
	
Gene Primer Sequence 
mRps9 F GCAAGATGAAGCTGGATTAC 
mRps9 R GGGATGTTCACCACCTG 
mNqo1 F AGGATGGGAGGTACTCGAATC 
mNqo1 R AGGCGTCCTTCCTTATATGCTA 
mHmox1 F AAGCCGAGAATGCTGAGTTCA 
mHmox1 R GCCGTGTAGATAATGGTACAAGGA 
mCypya1-F CTCTTCCCTGGATGCCTTCAA 
mCypya1-R GGATGTGGCCCTTCTCAAATG 
mAreg-F GGTCTTAGGCTCAGGCCATT 
mAreg-R AGAGTTCACTGCCAGAAGGC 
mAhr-F CGGAGCGCTGCTTCCTCCAC 
mAhr-R GCTGCCCTTTGGCATCACAACC 
mEgf-F AGGATCCTGACCCCGAACTT 
mEgf-R  ACAGCCGTGATTCTGAGTGG 
mEpgn-F TGGCTCTGGGGGTTCTGATA 
mEpgn-R TGTAGTCAGCTTCGGTGTTGT 
mEreg-F TGCTTTGTCTAGGTTCCCACC 
mEreg-R CGGGGATCGTCTTCCATCTG 
mHbegf-F TTTCTGGCCGCAGTGTTGTC 
mHbegf-R GTGGGTAGCAGCTGGTTTGT 
mNrg1-F GCAAAGAAGGCAGAGGCAAG 
mNrg1-R AATCTGGGAGGCAATGCTGG 
mNrg2-F CACTCTGTCATCCTGGTCGG 
mNrg2-R TCAGCCTTTTGCTTAGGATCTGG 
mNrg3-F CCTATCAAGCACCACAGCCC 
mNrg3-R CCTGACCTCTATCCCTTGGC 
mNrg4-F TACGACGAGAGAAGTCCCAG 
mNrg4-R TAGCAGGGTGCAAGGTCAAC 
mTgf_alpha_F TAGCGCTGGGTATCCTGTTAG 
mTgf_alpha_R GAGTGTGGGAATCTGGGCAC 
mEgfr-F CACGCCAACTGTACCTATGGATGT 
mEgfr-R GGCCCAGAGGATTTGGAAGAA 
mErbb2-F GGCACTGTCTACAAGGGCAT 
mErbb2-R GAGGCGGGACACATATGGAG 
mErbb3-F CACCCAAGGGTGTAAGGGAC 
mErbb3-R CGCTCCAAGTAGCGTCTCAT 
mErbb4-F GGACGGGCCATTCCACTTTA 
mErbb4-R AAGGGCTCTACCAGCTCTGT 
SI Appendix Table 2: Primers used for ChIP-qPCR (m=mouse) 
mAreg_XRE_F ttctccccgcgtaatcagg 
mAreg_XRE_R gccgggaggttactactccaa 
mCyp1a1_XRE_F caggcaacacagagaagtcg 
mCyp1a1_XRE_R aagcatcaccctttgtagcc 
 
 
